Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Back to $28s today. Guess another wait for earning release for the break out -- it's got to happen sometime.
a year and 2 months ago 28.48 if I recall and at least a year and half before that...It felt different on this run up. Maybe it's still different and going to set a new trading range to play in.
i think been 3 years since BHC/VRX was in the mid-to-high $28s.
Yeah the big question is why. I'm just hoping that suddenly its on a bunch of institutions "buy" list now.
Finally!
We passed this path of misery:)
what a run! Anyone sweating from euphoria or FEAR?
yup sure looks like accumulation to me.
Great 3 weeks: $19s,$20,21,22,23,24,25,26,27,$28+
Its done nothing but go up no matter what the markets are doing for the past month.
I really think you are right and l hope it is coming next year! BHC still have a lot of debt. However, they showed an amazing improvement!
On a technical basis, we need to see the RSI come down below 50. Consolidating at this price would be the best outcome in the near term.
JMO
For a company that has grown for 5 Qs in a row and been paying hundreds-of-millions in debt/year, it should hit $60s. BHC should get the benefit of the speculative doubt imo. I think $60 is coming.
Bausch Health Rises After Strong Sales, Boost in 2019 Revenue Guidance
Sales rise to $2.21 billion in the latest quarter from $2.14 billion a year earlier.
Dan Weil
Nov 4, 2019
Shares of Bausch Health (BHC - Get Report) , formerly known as Valeant, rose Monday after third-quarter revenue exceeded expectations, and the pharmaceutical company increased its revenue guidance.
Bausch Health, based in Laval, Canada, reported a loss of $49 million, or 14 cents a share, in the latest quarter, shrinking from a loss of $350 million, or $1 a share, a year ago.
Adjusted net income was $425 million, up from $403 million a year earlier. The company didn't offer adjusted earnings per share data. Analysts estimated adjusted EPS would total $1.09 in the third quarter.
Revenue climbed to $2.21 billion in the latest quarter from $2.14 billion a year earlier. Analysts predicted sales of $2.16 billion for the third quarter.
Breaking down sales by division, at Bausch & Lomb/International sales gained 2% to $1.175 billion; at Salix, they increased 20% to $551 million; at ortho dermatologics, they slid 16% to $147 million; diversified products revenue fell 5% to $336 million.
In terms of guidance, Bausch Health now anticipates revenue of $8.475 billion to $8.625 billion for all of 2019, up from its previous guidance of $8.4 billion to $8.6 billion.
Bausch Health CEO Joseph Papa touted strength in the company's older brands, such as Xifaxan, BioTrue Oneday and Bausch + Lomb Ultra. He lauded the success of newer products, such as Lumify and Thermage.
"Additionally, we are excited by the potential we see from the early days of the launch of Duobrii, the newest product in our dermatology portfolio," Papa said in a statement.
Breakout to $33 perhaps.
It looks like we on the right path, finally up!
$26.20 -- Beginning of breakout to $60 finally????
BHC on cusp of making outright profit (instead of adjusted). Probably depends on success of DOUBRII.
Someday there has to be a BREAKOUT, but so far BHC has always gone down from $27 (since VRX demise from what? $200++).
Already did at the open. They doubled on the dip but it’s insurance for my position.
If history is any guide ...
BHC has topped out.
Perhaps a good time to buy Puts.
I wanted to trade BHC, but
I was already in an AMD trade, and BHC (if it trades like it has been for many moons) is very risky to hold as earnings are reported, as everyone seems to want to take profits then.
Last May would be an example -- BHC went higher immediately after earnings were reported then immediately reversed on the following day. Granted, that wont go on forever but I don't like to gamble.
I think that kind of pattern exists when traders are in control of the majority of shares rather than investors being in control.
I got really lucky on my Nov 25 calls and Jan 30 calls.
Nov 25's bought .15 sold .40 bought back .31 sold .75-.85 but went to 1.50's Friday.
Jan 30's made 100% and want to keep them but 19's to 26 in weeks right before an ER was good enough. I'm not greedy and will play accordingly Monday. Not sure which direction and might play both ways being the ER premium will be gone.
I thought BHC (VRX) would hit $60s a year ago. Wrong..wrong..wrong.
My guess: after earnings: either goes to $30 or back to $19.
my gyess ,, my guess
$25+ hit. Pretty impressive run UP. $19s to $25s almost in a straight line and in a few days.
Hit $24.98 before backing off some. Hmmm Hmmm
I hope for &35 soon, it is time!
BHC: $19s>$20s>>$21s>>$22s>>$23s>>$24s-->??$25s???
Bullish flag breakout rules:
You should have bought on Friday. That was breakout day.
Look at what it did last January.
According to history you should own BHC going into earnings then sell immediately after earnings on any signs of weakness. But even that can be dicey as there are too many traders trading the horizontal range. And it is made worse because the company announces earnings before the market opens.
I would have entered a BHC trade on Friday but couldn't because I was in another trade. If it retraces more of Friday's gain, I'll likely take the trade.
Yep we saw it then and still in effect now. Trade this puppy all year long...22 Buy/26 sell PROFIT... I think it's going to create a new trend higher with Citron report but until it does these numbers are in effect.
26 is coming the question is before or days after ER. Need to hold 22.50 before ER then see a 26-26.50 push. Looking at history it pushed towards 28 a year ago. Under 22 will be hard if Trump China do trade deal lite...
Easily under if Trump tweet storm attacking China. So either direction possible. LOL
Thanks. That explains the constant rise today.
BHC for Wednesday,
History sometimes repeats.
I believe it has a potential to go to 26 on an earnings report which isn't far off, but count on a quick reversal according to history. It really likes to do that reversal thingy at 26. So as I explained earlier, I want it trade horizontally a bit with the hope I can buy it at $22 or lower. The result of that is a bullish flag pattern which has a potential maximum rise equal to the height of the pole, so that would be an earnings-induced quick spike higher to 26. Hit that -- dump it or write Deep ITM CCs.
I'm planning optimistically, and could be totally wrong. A huge gain or a nothing burger. That flag last January was mostly green volume. Had two red days already in this flag and will have more red if the downtrend continues.
Earnings is scheduled for the morning of Monday, Nov 4.
Respecting downtrend.
Since I'm out of BHC, it worked out pretty well for me to turn off the computer and go shopping this morning. Got back a couple hours ago. I was surprised to see the market had closed down. I didn't expect that as I turned of the computer this morning.
If my system was in a Buy mode going into today, it would have issued a Sell signal today because of the position of the open and both the size and close of this day's candlestick body relative to its shadows and previous day's trade.
Not that that would have mattered because the system issued a sell signal yesterday, so I had no intention of going long anything today under normal circumstances, and that's why I went shopping.
Don't ask me to explain my system. I've been away from its innards so long that I couldn't easily explain it and it requires a Venn diagram to explain it and even that is difficult for me to follow even though I made the dang thing.
A weakness of the system is that it gives no clue about tomorrow most of the time, so I have to do like everyone else -- rely on hunch.
Down $.33 already, but did hit $23s again briefly.
This stock has to go up! It incredibly undervalued!!
Citron bullish on Bausch Health, shares up 3%
Oct. 15, 2019 11:24 AM ET|About: Bausch Health Companie... (BHC)
|By: Douglas W. House, SA News Editor
Bausch Health Companies (BHC +3.3%) perks up on almost 50% higher volume in reaction to a bullish report from original bear Citron Research.
Citron believes the stock could rise 84% to $40 as investors come around to its improved financial health, adding that the company has delivered two consecutive quarters of EBITDA growth, six consecutive quarters of organic revenue growth, launched products that could generate more than $1B in peak sales by the end of 2022 and cut debt by $8B since early 2016.
Citron was an early bear on Valeant Pharmaceuticals under then-CEO Mike Pearson.
Overhead Resistance:
Changed SupRes line to red because it's close and it's resistance. I also wrote earlier that it's likely to act as it did at this level and similar circumstances last January. I don't want to ride a repeat of that. But if it repeats that corrective action and the juju is right I'll try to buy back in at the bottom of the corrective bounce lower and write overhead CCs very quickly.
Something to listen to ...
after you've just sold all your BHC stock.
http://tinyurl.com/y4t73yts
Followers
|
92
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5042
|
Created
|
05/15/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |